Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) announced that their Phase 3 INTerpath-001 trial of intismeran autogene in combination with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE